Literature DB >> 16849343

Interfering with interferons in inflammatory bowel disease.

S Ghosh1, R Chaudhary, M Carpani, R Playford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16849343      PMCID： PMC1856258          DOI： 10.1136/gut.2005.090134

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  22 in total

1.  An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis.

Authors:  S M Madsen; P Schlichting; B Davidsen; O H Nielsen; B Federspiel; P Riis; P Munkholm
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

2.  Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

Authors:  R A Rudick; R M Ransohoff; R Peppler; S VanderBrug Medendorp; P Lehmann; J Alam
Journal:  Ann Neurol       Date:  1996-10       Impact factor: 10.422

3.  Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.

Authors:  Eugen Musch; Tilo Andus; Wolfgang Kruis; Andreas Raedler; Martina Spehlmann; Stefan Schreiber; Bernd Krakamp; Mouhamad Malek; Helmut Malchow; Filip Zavada; Gerhard Engelberg Feurle
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

4.  Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis.

Authors:  Yuriko Tsukada; Tetsuo Nakamura; Mitsutoshi Iimura; Bun-ei Iizuka; Naoaki Hayashi
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

5.  Anti-interleukin-12 antibody for active Crohn's disease.

Authors:  Peter J Mannon; Ivan J Fuss; Lloyd Mayer; Charles O Elson; William J Sandborn; Daniel Present; Ben Dolin; Nancy Goodman; Catherine Groden; Ronald L Hornung; Martha Quezado; Zhiqiong Yang; Markus F Neurath; Jochen Salfeld; Geertruida M Veldman; Ullrich Schwertschlag; Warren Strober
Journal:  N Engl J Med       Date:  2004-11-11       Impact factor: 91.245

6.  Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.

Authors:  S A Brod; G D Marshall; E M Henninger; S Sriram; M Khan; J S Wolinsky
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

7.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

8.  Suppressor T cell activation by human leukocyte interferon.

Authors:  H W Schnaper; T M Aune; C W Pierce
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

9.  Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss.

Authors:  S Acciuffi; S Ghosh; A Ferguson
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

10.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.

Authors:  Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307
View more
  11 in total

1.  Interfering with interferon-γ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein.

Authors:  D Schuhmann; P Godoy; C Weiss; A Gerloff; M V Singer; S Dooley; U Böcker
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

2.  A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation.

Authors:  David Padua; Swapna Mahurkar-Joshi; Ivy Ka Man Law; Christos Polytarchou; John P Vu; Joseph R Pisegna; David Shih; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-04       Impact factor: 4.052

Review 3.  Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Authors:  Guillaume Bouguen; Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 4.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases.

Authors:  Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Immunity       Date:  2009-10-16       Impact factor: 31.745

5.  Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding protein.

Authors:  Anthony A Nuara; Leigh J Walter; Naomi J Logsdon; Sung Il Yoon; Brandi C Jones; Jill M Schriewer; R Mark Buller; Mark R Walter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-05       Impact factor: 11.205

6.  Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy.

Authors:  Emine Guven-Maiorov; Saliha Ece Acuner-Ozbabacan; Ozlem Keskin; Attila Gursoy; Ruth Nussinov
Journal:  Cancers (Basel)       Date:  2014-03-25       Impact factor: 6.639

7.  Adoptive Transfer of Dendritic Cells Expressing Fas Ligand Modulates Intestinal Inflammation in a Model of Inflammatory Bowel Disease.

Authors:  Edelmarie Rivera de Jesus; Raymond A Isidro; Myrella L Cruz; Harry Marty; Caroline B Appleyard
Journal:  J Clin Cell Immunol       Date:  2016-04-29

8.  Development of a Gut-On-A-Chip Model for High Throughput Disease Modeling and Drug Discovery.

Authors:  Claudia Beaurivage; Elena Naumovska; Yee Xiang Chang; Edo D Elstak; Arnaud Nicolas; Heidi Wouters; Guido van Moolenbroek; Henriëtte L Lanz; Sebastiaan J Trietsch; Jos Joore; Paul Vulto; Richard A J Janssen; Kai S Erdmann; Jan Stallen; Dorota Kurek
Journal:  Int J Mol Sci       Date:  2019-11-12       Impact factor: 5.923

Review 9.  Type I interferons for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; John K MacDonald; Eric I Benchimol; Anne Marie Griffiths; A Hillary Steinhart; Remo Panaccione; Cynthia H Seow
Journal:  Cochrane Database Syst Rev       Date:  2015-09-14

Review 10.  Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.

Authors:  Bruno Rafael Ramos de Mattos; Maellin Pereira Gracindo Garcia; Julia Bier Nogueira; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luís Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.